Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Javier Nieto.
American Journal of Kidney Diseases | 2013
Gema Fernandez Juarez; José Luño; Vicente Barrio; Soledad García de Vinuesa; Manuel Praga; Marian Goicoechea; Victoria Cachofeiro; Javier Nieto; Francisco Fernández Vega; Ana Tato; Eduardo Gutierrez
BACKGROUND Blockade of the renin-angiotensin system with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers has been shown to lessen the rate of decrease in glomerular filtration rate in patients with diabetic nephropathy. STUDY DESIGN A multicenter open-label randomized controlled trial to compare the efficacy of combining the angiotensin-converting enzyme inhibitor lisinopril and the angiotensin II receptor blocker irbesartan with that of each drug in monotherapy (at both high and equipotent doses) in slowing the progression of type 2 diabetic nephropathy. SETTING & POPULATION 133 patients with type 2 diabetic nephropathy (age, 66 ± 8 years; 76% men) from 17 centers in Spain. INTERVENTION Patients were randomly assigned (1:1:2) to lisinopril (n = 35), irbesartan (n = 28), or the combination of both (n = 70). OUTCOMES The primary composite outcome was a >50% increase in baseline serum creatinine level, end-stage renal disease, or death. RESULTS Baseline values for mean estimated glomerular filtration rate and blood pressure were 49 ± 21 mL/min/1.73 m(2) and 153 ± 19/81 ± 11 mm Hg. Mean geometric baseline proteinuria was protein excretion of 1.32 (95% CI, 1.10-1.62) g/g creatinine. After a median follow-up of 32 months, 21 (30%) patients in the combination group, 10 (29%) in the lisinopril group, and 8 (29%) in the irbesartan group reached the primary outcome. HRs were 0.96 (95% CI, 0.44-2.05; P = 0.9) and 0.90 (95% CI, 0.39-2.02; P = 0.8) for the combination versus the lisinopril and irbesartan groups, respectively. There were no significant differences in proteinuria reduction or blood pressure control between groups. The number of adverse events, including hyperkalemia, was similar in all 3 groups. LIMITATIONS The study was not double blind. The sample size studied was small. CONCLUSIONS We were unable to show a benefit of the combination of lisinopril and irbesartan compared to either agent alone at optimal high doses on the risk of progression of type 2 diabetic nephropathy.
American Journal of Nephrology | 1987
Manuel Praga; Pilar Diaz Rubio; José M. Morales; Francisca Cañizares; Luis M. Ruilope; Victor Gutierrez-Millet; Javier Nieto; Jose L. Rodicio
Serum levels of vitamin A (VA) were measured in 71 hemodialysis (HD) patients and in 30 normal controls. 65 of the 71 patients were taking multivitamin preparations (MP) containing VA. The HD patients had significantly greater values: 7.81 +/- 2.86 mumol/l (224 +/- 82 micrograms/dl) versus 3.97 +/- 0.97 mumol/l (114 +/- 28 micrograms/dl; p less than 0.0005); those taking MP with large doses of VA showed the highest levels. Patients were divided as having normal (group I, n = 21) or elevated (group II, n = 50) serum levels of VA. Patients of group II had higher levels of serum calcium (Ca) and lower of serum phosphate (P) and PTH than those of group I. Four months after the withdrawal of oral VA, the serum levels of VA and Ca fell significantly in group II, while the serum P increased. On the contrary, in group I serum levels of VA, Ca and P remained unchanged. Serum triglycerides (TG) were significantly higher in group II but did not change after the withdrawal of VA. No differences between both groups of patients were observed for age, time on HD, residual diuresis, residual renal function, serum levels of cholesterol (CL) or anemia. A retrospective study of 18 hepatic biopsies of HD patients disclosed hyperplasia of Ito cells (VA-storaging cells) in 7 of them. These 7 biopsies belonged to patients who had taken large amounts of oral VA. Our data indicate that prolonged VA intake in HD patients is followed by an increase of serum CA, a decrease of serum P and PTH and a hepatic accumulation of VA.(ABSTRACT TRUNCATED AT 250 WORDS)
JAMA Internal Medicine | 1986
Victor Gutierrez-Millet; Javier Nieto; Manuel Praga; Gabriel Usera; Miguel A. Martinez; José M. Morales
Nephrology Dialysis Transplantation | 1994
R. Peces; R. Enriquez de Salamanca; A. Fontanellas; A. Sánchez; M. de la Torre; Guadalupe Caparrós; I Ferreras; Javier Nieto
International Journal of Cardiology | 2006
Carmen Suárez; José Villar; Nieves Martel; Blas Gil Extremera; Najaty Suliman; Carlos Campo; Victoriano Castellanos; Antonio Liébana; Enrique Rodilla; Javier Nieto; Olga Velasco; Luis M. Ruilope
Nefrologia | 2005
Jesús Blanco; Lizeth Rodríguez González; C. Vozmediano; Tania Alvarez; M De la Torre; Francisco Rivera Hernández; Javier Nieto; María Dolores Sánchez de la Nieta
American Journal of Hypertension | 2003
Julian Segura; Carlos Campo; Javier Nieto; Alberto Torres; Fernando De Alvaro; Ana Vigil; José Luño; Luis M. Ruilope
Sanidad militar: revista de sanidad de las Fuerzas Armadas de España | 1999
R Alcázar; Miguel de la Torre; María Dolores Sánchez de la Nieta; Guadalupe Caparrós; Javier Nieto; I Ferreras
Transplantation Proceedings | 1998
M.M. de la Torre; R Alcázar; J.M Urra; Guadalupe Caparrós; R Alegre; Jesús Blanco; Javier Nieto; I Ferreras
Nephrology Dialysis Transplantation | 2017
Carreño A; Javier Lorente; Javier Nieto; Luis Piccone; Marco Douze; Mayberi del Cisne MAldonado; C. Vozmediano